Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (Nhl) With Lisocabtagene Maraleucel in the Outpatient Setting: Results From Two Phase 2 Trials
Hematological Oncology - United Kingdom
doi 10.1002/hon.185_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley